Recombinant Proteins Market Size, Share, Trends and Forecast, 2026 to 2034
REPORT DETAILS
Recombinant Proteins Market Summary
The global recombinant proteins market size was valued at USD 2.71 billion in 2025. The market is projected to grow at a CAGR of 12.00% during 2026 to 2034. Key factors driving demand for recombinant proteins include the increasing global burden of chronic and genetic diseases and significant investments in biopharmaceutical research and development.
Market Statistics
Key Takeaways
- North America led the market with 41.76% share in 2025, supported by high biopharma R&D spending and a deep base of research institutions.
- Asia Pacific is the fastest-growing region, currently holding an estimated 24.72% share, with China, India and Japan expanding biomanufacturing capacity and research funding.
- The product segment held an 88.36% share in 2025, with production services making up the rest as more developers outsource expression work.
- Enzymes held an 11.24% share of product revenue in 2025 and are expected to grow fastest among product types, helped by their use across oncology, wound repair, transplantation and metabolic research.
- Therapeutics is the largest application, accounting for an estimated 33.86% share in 2025, reflecting how central recombinant proteins have become to biologics, vaccines and cell and gene therapies.
- Pharmaceutical and biotechnology companies are the dominant end users, holding an estimated 39.18% share in 2025, as discovery, assay development and process work all consume recombinant proteins.
Note: Figures and projections outlined in this report are the result of Polaris Market Research’s proprietary analytical processes, grounded in the latest available datasets and market observations.
Recombinant Proteins Market Definition and Growth Analysis
Recombinant proteins are engineered proteins. Host cells produce these proteins using recombinant DNA (artificially modified DNA) rather than their natural genetic blueprint. Because the gene sequence is defined, the resulting protein is homogeneous between batches and doesn’t have the batch-to-batch variability or risk of contamination that can be associated with proteins derived from blood or tissue. That dependability is the reason that recombinant DNA technology is now a cornerstone for the biotechnology industry. This report covers recombinant proteins sold as research grade and GMP grade reagents, raw materials and production services to pharmaceutical, biotechnology, academic and diagnostic customers. It excludes finished biologic drugs such as insulin and monoclonal antibody therapies.
The market caters to a wide product range. Cytokines and growth hormones, such as interferons and interleukins, fuel cell culture and immunology experiments. Antibodies and immune checkpoint proteins promote research in oncology as well as assay development. Enzymes, including kinases and metabolic enzymes, provide the basis for screening and diagnostics, and virus antigens supply vaccine and serology programs. Hormones, regulatory proteins and contract production services also form part of the offer.
There are three fronts from which competing demand for protein expression and purification services is advancing: academic and institutional science, drug maker discovery and development, and biologics and advanced therapy manufacturing. Improved expression systems, higher-yield cell lines, and more recently, artificial intelligence (AI) aided protein design, are reducing the cost and time to generate novel proteins. It is further expanding the number of experiments and products reliant on them.
Comparison Between Recombinant Proteins Vs Traditional Biologics
| Parameter | Recombinant Proteins | Traditional Biologics |
| Production Method | Produced using recombinant DNA technology in engineered host cells | Derived from natural biological sources such as blood, tissues, or living cellular organisms, and natural sources. |
| Consistency | High batch-to-batch consistency due to controlled genetic engineering | Greater variability due to dependence on natural extraction processes |
| Scalability | Easier large-scale production with optimized cell culture systems | More complex scaling due to source limitations and purification challenges |
| Purity | Higher purity and targeted protein expression | May contain impurities from natural biological materials |
| Safety | Lower risk of contamination and pathogen transmission | Higher risk of contamination from biological source materials |
| Cost Efficiency | More cost-effective in long-term commercial production | Often higher production and purification costs |
Source: Polaris Market Research Analysis
The demand for the recombinant proteins market is expected to be driven by the increasing industry-academia collaborations and rising government funding. The production procedure of recombinant protein requires a technology called recombinant DNA (rDNA) technology which then produces a large number of proteins and other commercial products. Increasing levels of chronic diseases and markets focusing more on protein curatives can also be considered to drive market growth. Furthermore, the rise in demand for biological products, production of recombinant DNA from various sources, and alternatives of basic proteins is likely to complement market growth.
AI Impact on the Recombinant Proteins Market
- AI helps in the design and testing of recombinant proteins.
- AI models predict protein folding and stability.
- AI improves production yields.
- AI tailors recombinant protein therapies to patient-specific genetic.

Market Dynamics
Driver Impact Analysis
| Market Driver | Relative Impact | Geographic Relevance | Timeline |
| Rising burden of chronic and genetic diseases | High | Global | Short to Medium Term |
| Growth in biopharmaceutical R&D and biologics pipelines | High | North America, Europe, China | Medium Term |
| Demand for GMP-grade proteins in cell and gene therapy | Medium | North America, Europe | Medium to Long Term |
| AI-assisted protein design and new protein formats | Medium | North America, Europe | Long Term |
Source: Polaris Market Research Analysis
Driver: Rising Burden of Chronic and Genetic Diseases
Cancer, diabetes, autoimmune disorders and rare genetic diseases are increasing in incidence with aging populations and lifestyle risk factors. Many of the leading treatments for these diseases are protein based drugs, and developers of insulin, monoclonal antibodies and enzyme replacement therapies use recombinant proteins in research, process development and production. Each new treatment also generates demand for research, as new therapies require recombinant versions of disease targets, receptors and ligands to test for potential drug candidates and to develop assays. Consequently, the demand expands as the incidence of diseases expands, both in the research and the therapeutic areas of the market.
Driver: Expanding Biopharmaceutical R&D and Biologics Pipelines
Biologics comprise a large and rapidly growing portion of drug pipelines, with recombinant proteins being used at every step of biologics development. They are used by discovery teams as targets and reagents, by analytical teams as reference standards, and by process developers to optimize cell culture media. This demand is driven by increasing R&D budgets, industry-academia collaborations, and government research funding. The advent of biosimilar programs, driven by the patent expiration of top-selling biologics, adds another layer of constant consumption through the need for analytical and comparability work, as well as other requirements like biological safety testing.
Restraint: High Production Cost and Expression Complexity
Production of the recombinant protein with correct folding, proper modifications and stability remains challenging and costly. Complex proteins frequently require mammalian expression systems, which are more time-consuming and expensive than bacterial systems; and the addition of GMP-grade production introduces validation, documentation, and quality testing. Purification can represent a significant portion of total cost. For academic labs and small biotech, these costs are likely to constrain the use of high-end proteins, and for suppliers, they represent an even steeper challenge to profitable catalog expansion into more difficult to express targets.
Opportunity: Cell and Gene Therapy Manufacturing Demand for GMP-Grade Proteins
Cell therapies, including CAR-T, rely on recombinant cytokines and growth factors to stimulate and expand patient cells, and gene therapy manufacturing depends on recombinant enzymes and supplements throughout production. With these programs transitioning from clinical to commercial supply, the mode of demand is changing from research-grade to GMP-grade proteins, that are fully traceable, a product of higher value that very few suppliers are capable of providing in large quantities. To capitalize on this demand, suppliers should demonstrate GMP protein capability and have regulatory documentation in place.
Opportunity: AI-Driven Protein Design and Next-Generation Formats
AI models predicting protein structure, fold and stability are reducing time from a design concept to a functional protein. Computational design binders, bispecific formats and stabilized variants are beginning to be included in commercial catalogs, as exemplified in the case of Bio-Techne's licensing of AI-designed bispecific binding proteins from Monod Bio. AI is further being used to enhance expression yields and to personalize protein therapies to the biology of the individual patient. Vendors that integrate design tools with dependable expression and quality control, on the other hand, can create a whole new product line rather than fighting it out over existing catalogs.

Recombinant Proteins Market Segment Analysis
The report provides a comprehensive analysis of the recombinant proteins market by product & services, application, end use, and region to identify key revenue-generating and high-growth segments.
Product & Services Insights
The products segment accounted for most of the market with 88.36% share of revenue in 2025. Within the product revenue, enzymes held an estimated 11.24% share and are expected to grow fastest among product types. Enzymes are widely used in various types of research, including oncology, wound repair, transplantation, and metabolic disease, and are also employed in therapeutic applications such as adjunctive treatments to chemotherapy and in the management of chronic diseases like diabetes. Production services represent the smaller half of this axis, and are primarily used by developers who prefer to outsource expression and purification rather than developing in-house capacity.
Cytokines and growth factors are a key part of the product catalog, and are used to grow, differentiate and stimulate cells in culture. Interferons and interleukins are the foundation of immunology research, and recombinant growth factors G-CSF are also used clinically, for example in the treatment of chemotherapy-induced neutropenia. The demand is progressively divided between research-grade material for discovery work and GMP-grade material for cell therapy manufacturing, with purity, consistency and documentation driving a meaningful price premium. The method used to produce a recombinant protein influences its cost, speed and biological quality. The table below summarizes the primary recombinant protein expression systems and their applications.
| Expression System | How It Works | Typical Proteins | Relative Cost & Speed | Modification Fidelity |
| Bacterial (E. coli) | Fast-growing bacteria express the target gene in large volumes | Enzymes, simple growth factors, research reagents | Lowest cost; fastest | Limited — no human-like glycosylation |
| Yeast | Engineered yeast secrete or retain the protein | Research grade proteins and vaccine antigens | Low to moderate | Partial — glycosylation differs from human |
| Insect Cell (Baculovirus) | Virus-infected insect cells express complex proteins | Kinases, viral antigens, structural-biology targets | Moderate | Good folding; simpler glycosylation |
| Mammalian (CHO, HEK293) | Mammalian cell lines produce near-native human proteins | Antibodies, therapeutic proteins, complex receptors | Highest cost; slowest | Highest — closest to human proteins |
Source: Polaris Market Research Analysis
Application Insights
Therapeutics is the largest application. The segment held a 33.86% share in 2025. Recombinant proteins are the basis of modern medicine such as biologics, vaccines, cell and gene therapies and therapeutic programs use proteins at every stage from target validation to process development and quality control. Drug discovery and development is a related, rapidly growing application, as the target pipelines are increasingly enriched with biologics, and basic research continues to be a large, stable demand driver from universities and institutes.
| Dimension | Drug Discovery & Development | Therapeutics | Research |
| Primary buyer | Pharma and biotech discovery teams, CROs | Biologics and advanced-therapy developers and manufacturers | Universities, institutes, core facilities |
| Quality grade needed | Research to high-purity | High-purity to GMP | Research grade |
| Typical use | Screening, assay development, target validation | Biologics, vaccines, cell and gene therapy production and testing | Mechanistic studies, cell culture, structural biology |
| What drives demand | Pipeline size and new target classes | Approvals, clinical progression, manufacturing scale-up | Grant funding and publication activity |
Source: Polaris Market Research Analysis
End Use Insights
The pharmaceutical and biotech companies segment held the largest share of 39.18% in 2025. These companies purchase recombinant proteins for the entire development process to predict and validate drug activity, develop diagnostic and potency assays, and for supply manufacturing processes, and multiple industry partnerships continue to drive that consumption. The second largest segment is the academic and research institutes and they continue to be the early-stage discovery source, while diagnostic laboratories utilize recombinant antigens and enzymes in laboratory and test kit-based solutions.
Recombinant Protein Types and Their Research and Therapeutic Use Cases
Each recombinant protein type serves a distinct job in research and therapeutic use cases, and the table below sets out what each type does, who relies on it, and the trade-offs buyers weigh.
| Recombinant Protein Type | What It Does | Typical End Use | Key Advantage | Limitation / Consideration |
| Cytokines & Growth Factors (incl. interferons, interleukins) | Signal cells to grow, differentiate or respond immunologically | Cell culture, cell therapy expansion, immunology research, supportive care such as neutropenia management | Consistent activity lot to lot versus native extracts | GMP grades are costly; activity can vary between suppliers |
| Antibodies | Bind specific targets with high selectivity | Cancer therapy, diagnostics, assay development | Defined sequence gives reproducible results | Usually need mammalian expression, raising cost |
| Enzymes (kinases, metabolic enzymes) | Catalyze specific biochemical reactions | Drug screening, diagnostic test kits, metabolic research | Broad use across many research domains | Stability and storage requirements vary widely |
| Hormones | Replace or regulate physiological signals | Research on diabetes and endocrine signaling, GMP grade hormone proteins for development | Avoids animal-derived sources and supply limits | Tightly regulated as therapeutic products |
| Virus Antigens | Trigger or detect an immune response to a pathogen | Vaccine antigen development (e.g., hepatitis B surface antigen), serology testing | No live virus needed, improving safety | Often require adjuvants for strong immunity |
| Immune Checkpoint Proteins | Model immune-regulatory pathways such as PD-1/PD-L1 | Immuno-oncology discovery and binding assays | Enable screening of checkpoint-targeting drugs | Complex folding; quality critical for valid assay data |
Source: Polaris Market Research Analysis

Regional Insights
North America Recombinant Proteins Market Trends
North America led the global recombinant proteins market with an estimated 41.76% share in 2025. The region consists of top protein suppliers and companies; leading research universities and a dense network of biopharma R&D spend in the US. A high burden of chronic and infectious disease, an expanding patient population and strong healthcare expenditures in the U.S. maintain demand, while public reimbursement for treatment for certain chronic diseases facilitate therapeutic uptake. The region is also the focal point of commercial cell and gene therapy activity, accelerating the pull-through of GMP-grade protein demand more rapidly than other regions.
Europe Recombinant Proteins Market Trends
Europe holds an estimated 25.18% share of global revenue in 2025 and is a mature, research-intensive market. Major pharmaceutical and life science tools companies are headquartered in Germany, the U.K., France and Switzerland, and Europe has led in biosimilar adoption, which also creates analytical and comparability demand for recombinant reference proteins. Recombinant therapeutics commercial activity continues to increase. In May 2025, Finland-based Orion Corporation announced an agreement to market and distribute Shilpa Biocare’s recombinant human albumin in Europe (Source: orionpharma.com).
Asia Pacific Recombinant Proteins Market Trends
Asia Pacific is the fastest-growing region in this market, currently holding an estimated 24.72% share. China has emerged as a significant supplier of research-grade recombinant proteins and a growing biological development hub, with India also looking to boost domestic biomanufacturing with the help of government programs like Biopharma SHAKTI. Japan and South Korea are strong in the pharmaceutical and research areas, with aging populations in Japan and China driving higher rates of chronic disease. Governments in the region are also increasing hospital and clinical capacity, which drives demand for therapeutics as well as research.
Latin America and Middle East & Africa Recombinant Proteins Market Trends
Latin America and the Middle East & Africa remain smaller markets, together accounting for an estimated 8.34% share of global revenue in 2025. In Latin America, Brazil and Mexico are at the forefront, closely followed by a rise in biotechnology and public finance in vaccine and biologics manufacturing. Across the Middle East, Saudi Arabia, the UAE and Israel are investing in expanding research and life-science infrastructure, with the latter particularly noted for its biotech start-up culture. Expansion in these regions hinges strongly on investment in healthcare and research in general, and a significant portion of their supply is still imported.

Key Market Players & Competitive Insights
The recombinant protein market includes major life-science suppliers with extensive product ranges, as well as specialist vendors and companies that produce proteins on contract. Large firms benefit from scale, offering thousands of products for research and GMP use. They can also provide related tools, such as antibodies, assays and cell culture media, and support customers from early research through manufacturing. Smaller specialists often stand out through focused product lines, faster custom production or lower prices. Suppliers based in China are also becoming more competitive, particularly in the range of products they offer.
Two developments are changing the market. One is consolidation: Bio-Techne shareholders approved Merck KGaA’s planned acquisition of the company in September 2026. The deal would bring together two established suppliers once it receives the remaining regulatory approvals. The other is the growing role of technology. Companies are licensing AI-designed proteins and expanding cell-line development and GMP manufacturing capacity to meet the needs of cell and gene therapy makers.
Competitive Landscape Snapshot
| Company | Core Recombinant Protein Portfolio | Recent Strategic Move | Positioning |
| Bio-Techne Corporation | R&D Systems cytokines, growth factors and GMP proteins | Licensed AI-designed NovoBody Duo molecules from Monod Bio (Nov 2025); agreed to be acquired by Merck KGaA (Jun 2026) | Research and cell-therapy-grade proteins |
| Merck KGaA | Life-science reagents and bioprocessing portfolio | Pending acquisition of Bio-Techne | Discovery-to-manufacturing workflow breadth |
| Thermo Fisher Scientific | Gibco and PeproTech recombinant proteins and cell culture products | — | Scale and global distribution |
| Abcam (Danaher) | Recombinant antibodies and proteins | Operates within Danaher following its acquisition | Antibody and protein research reagents |
| GenScript | Protein expression and production services | — | Outsourced custom production |
| Sino Biological | Large recombinant protein and antibody catalog | — | Catalog breadth; China-based supply |
Source: Company filings and Polaris Market Research Analysis
Competitive Benchmarking
| Company | Core Recombinant Protein Portfolio | Positioning |
| Bio-Techne Corporation | R&D Systems and related brands: cytokines, growth factors, GMP-grade proteins, antibodies and immunoassay kits; ProteinSimple protein analysis instruments | Research- and cell-therapy-grade proteins; benchmark for cytokine and growth factor quality |
| Merck KGaA, Darmstadt, Germany | Life Science business (MilliporeSigma in the U.S. and Canada): recombinant cytokines, growth factors, chemokines, enzymes, kinases, receptors and hormones, plus bioprocessing materials | Discovery-to-manufacturing workflow breadth; scale in process solutions |
| Thermo Fisher Scientific, Inc. | Gibco, Invitrogen and PeproTech recombinant proteins; PeproGMP range for biotherapeutic and cell therapy developers; cell culture media | Scale, global distribution and integrated media-plus-protein offering |
| Abcam (part of Danaher Corporation) | Recombinant antibodies and recombinant proteins for research use | Antibody-led research reagents; access to Danaher’s life-science channels |
| Bio-Rad Laboratories, Inc. | Recombinant antibodies and proteins (Bio-Rad Antibodies, incl. HuCAL-derived formats) alongside assay and detection reagents | Antibodies and reagents validated on Bio-Rad instrument platforms |
| GenScript Biotech Corporation | Gene-to-protein platform: recombinant protein expression and production services, antibody discovery; ProBio CRDMO arm for antibody, protein and cell and gene therapy development | Outsourced custom production; integrated gene-synthesis-to-protein workflow |
| Sino Biological Inc. | 8,000+ recombinant proteins and 14,000+ antibodies; ProVir viral antigen bank; ProPure endotoxin-free proteins made at Houston Center for Bioprocessing | Catalog breadth and viral antigen depth; China-based supply with U.S. manufacturing |
| Enzo Life Sciences, inc. | Enzo Life Sciences: antibodies, assays, biochemicals, genomic probes and proteins for labeling and detection | Niche research reagent supplier under private-equity ownership |
| Proteintech Group, Inc. | Antibodies, recombinant proteins and ELISA kits for research | Antibody-led catalog with growing recombinant protein range |
| RayBiotech Life, Inc. | Cytokine antibody arrays, ELISA kits and recombinant proteins | Multiplex cytokine profiling specialist |
| STEMCELL Technologies Inc. | Cytokines and growth factors alongside cell culture media and reagents for stem cell and immune cell work | Cell-culture workflow specialist; proteins sold as part of media systems |
| Abnova Corporation | Recombinant proteins, antibodies, ELISA kits and cDNA clones | Taiwan-based, broad low-cost research reagent catalog |
| Aviva Systems Biology Corporation | Antibodies, ELISA kits and recombinant proteins | Research reagent supplier; antibody-weighted catalog |
| U-Protein Express B.V. | Contract protein expression and purification (bacterial, insect and mammalian systems) and related assay services | Custom expression services for academic and biotech clients |
| Shilpa Medicare Limited | Recombinant human albumin (in development) via subsidiary Shilpa Biocare Private Limited; biologics contract development and manufacturing | Emerging recombinant alternative to plasma-derived albumin; not yet commercial |
Source: Polaris Market Research Analysis
Future Outlook
During the forecast period, the recombinant proteins market is anticipated to continue transitioning towards higher-value products as opposed to expanding on the basis of research volume. Cytokines and growth factors at GMP grade for cell and gene therapy, high purity reference proteins for biosimilar development or engineered formats like bispecific binders all command superior pricing versus standard research reagents and their proportion of supplier revenue is expected to increase as advanced therapies transition to commercial manufacturing.
Technology will be doing much of the work. Recombinant design assistance: AI-assisted design is expected to reduce the time from protein design to a usable protein, while improved expression hosts and cell lines are expected to gradually reduce the cost of producing complex, human-like proteins. Recombinant substitutes for plasma-derived products, including for recombinant albumin, may provide an additional avenue for sustained growth in therapeutic supply.
On the competitive front, consolidation in life-science tools companies will likely continue, as the largest companies focus on providing full workflow solutions from discovery to manufacturing. However, in terms of geography, Asia Pacific is anticipated to continue capturing ground over the developed markets of North America and Europe as a result of the establishment of biomanufacturing facilities in India and China. Overall, the market appears to be poised for robust growth, with the mix moving toward GMP, engineered and therapeutic-grade proteins.
Analyst Perspective
The recombinant proteins market is progressing into the growth phase, where biopharma companies are increasingly dependent on recombinant protein based technologies for drug discovery, biologics development, vaccines, diagnostics and advanced therapies. Increasing applications of cytokines, growth factors, antibodies, enzymes and regulatory proteins in research as well as in commercial applications such as therapeutics and diagnostics are driving the demand. The market is also being propelled by increased funding in cell and gene therapy, for which high-purity recombinant proteins play a critical role in cell culture, signaling, differentiation and manufacturing processes.
Pharmaceutical/biotechnology firms will continue to be the primary end users from a market perspective and production services are anticipated to grow at a higher rate as these companies increasingly outsource specialized expression, purification and scale-up related tasks. Strong biopharmaceutical research and development and commercialization activity will help North America hold a commanding share of the market, while Asia Pacific will register the highest growth rate, owing to improving regional manufacturing capabilities, increasing research funding, and developing biotechnology ecosystems. During the forecast period the vendors that can produce high-purity, application-specific, and scalable recombinant proteins without compromising on the quality and that are capable of offering regulatory support shall be able to seize the maximum opportunity in the market.
Recent Developments
- June 2026, Merck KGaA agreed to acquire Bio-Techne in an all-cash deal; Bio-Techne shareholders approved the merger in September 2026, with closing expected late 2026 or early 2027. (Source: sigmaaldrich.com)
- November 2025: Bio-Techne Corporation signed a licensing agreement with Monod Bio, a Seattle-based biotechnology company, to expand its recombinant protein portfolio. (Source: bio-techne.com)
- September 2025: ARCHIMED acquired a majority stake in ExcellGene and Magellan Biologics & Consulting. With this, ARCHIMED focuses on expanding into biosimilars and high performance transfection solutions. It will enable high-performance production of recombinant proteins and other advanced therapeutics. (Source: archimed.group)
Key players in tge Recombinant Proteins Market
- Abcam (part of Danaher Corporation)
- Abnova Corporation
- Aviva Systems Biology Corporation
- Bio-Rad Laboratories, Inc.
- Bio-Techne Corporation
- Enzo Life Sciences, Inc.
- GenScript
- Merck KGaA
- Proteintech Group, Inc.
- RayBiotech Life, Inc.
- Shilpa Medicare Limited
- Sino Biological Inc.
- STEMCELL Technologies Inc.
- Thermo Fisher Scientific, Inc.
- U-Protein Express B.V.
Recombinant Proteins Market Segmentation
By Product & Services Outlook (Revenue - USD Billion, 2021 - 2034)
- Product
- Cytokines & Growth Factors
- Interferons (IFNs)
- Interleukins (ILs)
- Others
- Antibodies
- Immune Checkpoint Proteins
- Virus Antigens
- Enzymes
- Kinases
- Metabolic Enzymes
- Others
- Recombinant Regulatory Proteins
- Hormones
- Others
- Cytokines & Growth Factors
- Production Services
By Application Outlook (Revenue - USD Billion, 2021 - 2034)
- Drug Discovery & Development
- Therapeutics
- Biologics
- Vaccines
- Cell & Gene Therapies
- Others
- Research
- Others
By End-Use Outlook (Revenue - USD Billion, 2021 - 2034)
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Diagnostic Laboratories
- Others
By Regional Outlook (Revenue – USD Billion, 2021–2034)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Recombinant Proteins Market Report Scope
| Report Attributes | Details |
| Market Size in 2025 | USD 2.71 billion |
| Market Size in 2026 | USD 3.03 billion |
| Revenue Forecast in 2034 | USD 7.53 billion |
| CAGR | 12.00% from 2026 – 2034 |
| Base year | 2025 |
| Historical data | 2021 – 2024 |
| Forecast period | 2026 – 2034 |
| Quantitative units | Revenue in USD billion and CAGR from 2026 to 2034 |
| Segments Covered |
|
| Regional scope |
|
| Customization | Report customization as per your requirements with respect to countries, region, and segmentation |
Source: Polaris Market Research Analysis
Recombinant Proteins Market FAQ's
The market size was USD 2.71 billion in 2025 and is expected to reach USD 7.53 billion by 2034.
The Recombinant Proteins Market is growing at a CAGR of 12.0% during the forecast period.
North America dominated the market with a 41.76% share in 2025, supported by high biopharmaceutical R&D spending, a dense research base, and strong adoption of cell and gene therapies.
Recombinant proteins are proteins made by inserting a gene into a host organism, such as bacteria, yeast or mammalian cells, which then produces the protein in quantity. They are used in therapeutics, vaccines, diagnostics, and research because they are consistent, pure, and scalable.
Recombinant proteins are used to make biologic drugs and vaccines, to run diagnostic tests, and to power laboratory research and drug discovery. Common examples include insulin for diabetes, monoclonal antibodies for cancer, and the recombinant hepatitis B vaccine.
Recombinant proteins are produced from a defined gene in engineered cells, while traditional biologics are extracted from natural sources such as blood or tissue. This gives recombinant proteins better batch-to-batch consistency, higher purity, and a lower risk of contamination.
Asia Pacific is the fastest-growing region, driven by expanding biomanufacturing in China and India, rising research funding and a growing burden of chronic disease in aging populations such as Japan and China.
Enzymes are expected to be the fastest-growing product type, reflecting their wide use across research domains from oncology to metabolic disease.
Leading companies include Thermo Fisher Scientific, Merck KGaA, Bio-Techne, Abcam (Danaher), GenScript, Sino Biological and Bio-Rad Laboratories, alongside specialist suppliers and contract protein producers.
AI is helping scientists predict protein structure, folding and stability, which speeds up the design of new proteins and improves production yields. Suppliers are already licensing AI-designed binding proteins for commercial use.
Download Sample Report of Recombinant Proteins Market
Please fill out the form to request a customized copy of the research report.